Methods for the preparation of injectable depot compositions

• US 10,195,138 B2
• Filed: 07/11/2018
• Issued: 02/05/2019
• Est. Priority Date: 05/31/2010
• Status: Active Grant

• Current Assignee: Laboratorios Farmaceuticos Rovi, S.A. (Norbel Inversiones SL)
• Original Assignee: Laboratorios Farmaceuticos Rovi, S.A. (Norbel Inversiones SL)
• Inventors: Gutierro Aduriz, Ibon, Gomez Ochoa, Maria Teresa
• Primary Examiner(s): Peebles, Katherine
• Application Number:
  US16/032,270
• Publication Number:
  US 20180318208A1
• Time in Patent Office: 209 Days
• Field of Search: None
• CPC Class Codes: A61K 31/4196 1,2,4-Triazoles
• CPC Class Codes: A61K 31/4468 having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/551 having two nitrogen atoms, e.g. dilazep
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0002 Galenical forms characterised by the drug release technique; Application systems commanded by energy
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.

Claims

1. A method of treating schizophrenia or bipolar disorder, the method comprising administering to a subject in need thereof an amount of injectable depot composition sufficient to provide a therapeutic dose of risperidone, to form an implant in the subject, wherein the injectable depot composition consists of risperidone, and a polymeric solution of DMSO and PLGA copolymer, and wherein

the content of risperidone is 13% wt±

10%, based upon the weight of the composition, and the risperidone possesses a particle distribution selected from

a. not more than 10% of the total volume of the particles is smaller than 10 microns, not more than 10% of the total volume of particles is greater than 225 microns, and the d0.5 is in the range of 10-200 microns;

b. not more than 10% of the total volume of the particles is less than the range 1-10 μ

m, not more than 10% of the total volume of particles is greater than the range 225-400 μ

m, and the d0.5 of the size distribution is in the range of about 40-200 μ

m;

or

c. expressed as volume, d0.9 is about 150 to about 400 μ

m, d0.5 is about 40 to about 200 μ

m and d0.1 is about 10 to about 60 μ

m;

the mass ratio of DMSO to risperidone is 4.66±

10%;

1;

the mass ratio of polymeric solution to risperidone is about 6.66±

10%;

1;

the PLGA copolymer is an end-capped biodegradable poly(lactide-co-glycolide) copolymer having a monomer ratio of lactic acid to glycolic acid of 50;

50±

10% and an inherent viscosity in the range of 0.20±

10% dl/g to 0.50±

10% dl/g as measured in chloroform at 25°

C. at a concentration of 0.1% wt/v with an Ubbelohde size 0 c glass capillary viscometer;

the polymeric solution has a viscosity in the range of 0.5-3.0 Pa·

s±

10%; and

the amount of risperidone dissolved in the injectable composition is ≤

20% wt.

2. The method of claim 1, wherein the implant provides therapeutic plasma levels of the risperidone or metabolite thereof from within 1 day after administration throughout a dosing period of at least four weeks following administration thereof.

3. The method of claim 1, wherein the implant provides a risperidone+9-hydroxy-risperidone total plasma level within the range of about 5 ng/ml to about 80 ng/ml when about 116 mg to about 700 mg, respectively, of the injectable depot composition comprising about 25 mg to about 150 mg, respectively, of risperidone is administered to the subject.

4. The method of claim 1, wherein the implant provides a pharmacokinetic plasma profile, for the risperidone, and/or metabolite thereof, defined as follows

5. The method of claim 1, wherein the injectable depot composition is administered intramuscularly, intraperitoneally, intrathecally, intravaginally, subcutaneously, intracranially or intracerebrally.

6. The method of claim 1, wherein the injectable depot composition provides a satisfactorily controlled release profile throughout a dosing period of at least 21 days after administration, whereby the composition releases about 0.5% to no more than about 12% of its dose of risperidone within 24 hours after administration.

7. The method of claim 1, wherein the composition provides a substantially level plasma profile, for the risperidone, and/or metabolite thereof, of within ±

15% of the average or mean during a period of at least 14 days following administration of the composition to a subject, wherein the average or mean is calculated over the 14 days.

8. The method of claim 1, wherein the composition provides a substantially level plasma profile, for the risperidone, and/or metabolite thereof, of within ±

10% of the average or mean during a period of at least 14 days following administration of the composition to a subject, wherein the average or mean is calculated over the 14 days.

9. The method of claim 1, wherein the composition provides a substantially level plasma profile, for the risperidone, and/or metabolite thereof, of within ±

20% of the average or mean during a period of at least 28 days following administration of the composition to a subject, wherein the average or mean is calculated over the 28 days.

10. The method of claim 1, wherein the implant releases about 0.5% to no more than about 12% of its dose of risperidone within 24 hours after administration.

11. The method of claim 1, wherein the implant releases about 0.5% to no more than about 8% of its dose of risperidone within 24 hours after administration.

12. The method of claim 1, wherein the injectable depot composition is a sterilized composition.

13. The method of claim 1, wherein the PLGA copolymer has been sterilized prior to inclusion in the injectable depot composition or prior to addition of the DMSO.

14. The method of claim 1, wherein at least one of the risperidone and PLGA copolymer has been irradiated with beta-irradiation in the range of 5-25 KGy.

15. The method of claim 14, wherein the beta-irradiation is sufficient to reduce the molecular weight and intrinsic viscosity of the PLGA copolymer.

16. The method of claim 1, wherein the viscosity of the injectable depot composition is in the range of about 0.7 Pa·

s to about 4.0 Pa·

s.

17. The method of claim 1 further comprising providing a kit comprising at least a first container comprising the PLGA copolymer;

and at least a second container comprising the DMSO, wherein the risperidone is present in the first container, the second container or a third container.

18. The method of claim 17 further comprising mixing the PLGA copolymer, DMSO and risperidone to form the injectable depot composition prior to administration to the subject.

19. The method of claim 18, wherein the kit comprises about 25 to about 150 mg of risperidone.

20. The method of claim 17, wherein one or more of the containers is a syringe, vial or cartridge.

21. The method of claim 17, wherein at least one of the risperidone and the PLGA copolymer is present in solid form prior to mixing with the DMSO.

22. The method of claim 21, wherein risperidone and PLGA copolymer are present in the same container prior to mixing with the DMSO.

23. The method of claim 1, wherein the injectable composition is administered to the subject every four weeks, every five weeks, every six weeks, every two months, every three months, every four months, every five months, or every six months.

24. The method of claim 1, wherein the injectable composition is warmed or cooled prior to administration to the subject.

25. The method of claim 1, wherein at least one of the DMSO and polymeric solution has been filtered through a filtration medium having a nominal pore size of 0.22 microns or less.

26. The method of claim 1, wherein the injectable depot composition is administered to the subject in one or more injection sites or such that there is one point of needle entry and more than one injection site below the skin.